Meeting
2020 Genitourinary Cancers Symposium
Prospective observational study on pazopanib in patients treated for advanced/metastatic renal cell carcinoma (RCC): APOLON Study.
Authors
Philippe Barthelemy
Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Philippe Barthelemy , Laurence Albiges , Bernard Escudier , Thierry Lebret , Pierre Bigot , Ulrich Stein , Louis-Marie Dourthe , Jeannine De La Cruz , Malka Tindel , Antoine Thiery-Vuillemin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 629)
Abstract #
629
Poster Bd #
D15
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-word evidence in patients treated with pazopanib for advanced/metastatic renal cell carcinoma (mRCC): The APOLON study.
First Author: Antoine Thiery-Vuillemin
Poster
2018 ASCO Annual Meeting
Prospective, multinational, observational study of real-world treatment outcomes with pazopanib in patients with advanced or metastatic renal cell carcinoma (PRINCIPAL Study).
First Author: Manuela Schmidinger
Poster
2016 Genitourinary Cancers Symposium
RECORD-4 phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Final OS analysis.
First Author: Thomas Cosgriff
Poster
2014 Genitourinary Cancers Symposium
Liver metastases as predictors of outcome in renal cell carcinoma (RCC) patients (pts) treated with first-line sunitinib (SU) and sorafenib (SO).
First Author: Paolo Grassi